What Is the Treatment for High-Grade Squamous Intraepithelial Lesion?

High-grade squamous intraepithelial lesion, commonly called HSIL, is treated primarily by removing or destroying the affected tissue before it can progress to invasive cancer. The standard approach for cervical HSIL is an excisional procedure, most often a loop electrosurgical excision procedure (LEEP), which cuts away the abnormal area of the cervix. However, treatment isn’t one-size-fits-all: a subset of patients with the lower end of HSIL (graded as CIN 2 on biopsy) can be safely monitored rather than immediately treated, and newer evidence on HPV vaccination after treatment is changing how clinicians think about preventing recurrence.

Why HSIL Needs Attention

HSIL on a Pap smear or cervical biopsy means that cells on the surface of the cervix have changed in ways that carry a real risk of becoming cancerous if left alone. When a biopsy confirms CIN 2 or CIN 3 (the tissue-level grades that fall under the HSIL umbrella), the risk of progression justifies intervention. The distinction between CIN 2 and CIN 3 matters because their biology differs: CIN 2 lesions regress on their own more often, while CIN 3 is closer to a true precancer and rarely resolves without treatment. The goal in every case is to prevent cervical cancer while removing as little healthy tissue as possible, especially for people who want to have children in the future.

Excisional Treatment With LEEP

LEEP (also called LLETZ, for large loop excision of the transformation zone) is the most widely performed treatment worldwide. A thin wire loop carrying an electrical current shaves off the area of the cervix where abnormal cells grow. It can be done in an office setting under local anesthesia, takes only a few minutes, and provides a tissue sample that a pathologist can examine to confirm the diagnosis and check whether the edges (margins) are free of disease.

Margin status turns out to be one of the strongest predictors of whether the lesion comes back. In one study of women treated with LLETZ, those with clear margins had cure rates around 85%, compared with 50% when the margins were involved. Margin involvement carried roughly sixfold higher odds of treatment failure, and that mattered more than simply making a deeper cut.

After LEEP, overall recurrence rates for HSIL hover around 9–10% in most studies. A retrospective analysis of 343 patients found a post-LEEP recurrence rate of 9%, with persistent HPV infection, positive margins, glandular involvement, and CIN 3 histology all independently raising the odds.

Cold Knife Conization as an Alternative

Cold knife conization (CKC) is the older surgical option: a scalpel removes a cone-shaped piece of the cervix. It generally takes longer, requires anesthesia in an operating room, and involves more tissue removal. The advantage is that CKC produces cleaner tissue margins for pathology review and avoids the heat artifact that LEEP’s electrical current can create, which sometimes makes it harder for the pathologist to read the edges.

A large emulated-trial study found that women who had CKC had a lower risk of recurrence than those who had LEEP, with faster HPV clearance at three, six, and twelve months after the procedure.³ A meta-analysis focused on adenocarcinoma in situ (a glandular form of HSIL) found that positive margins were more common after LEEP (about 44%) than after CKC (about 29%), though actual recurrence rates were statistically similar between the two techniques.⁴ A cross-sectional study of over 300 LEEP patients and 35 CKC patients likewise found no significant difference in recurrence rates between the two procedures.⁵

In practice, most clinicians reserve CKC for situations where LEEP is less ideal: suspected glandular disease, lesions extending high into the cervical canal, or cases where a prior LEEP left positive margins and a second excision is needed. For straightforward squamous HSIL, LEEP remains the first choice because it is faster, cheaper, and can be done in an outpatient setting.

Ablative Approaches

Ablation destroys abnormal tissue in place rather than removing it. The two main options are cryotherapy (freezing) and thermal ablation (a heated probe). Because ablation does not produce a tissue specimen for pathology review, it is only appropriate when the diagnosis has already been confirmed by biopsy and the entire lesion is visible on the surface of the cervix.

Thermal ablation has gained traction, particularly in lower-resource settings, as a portable and inexpensive alternative to LEEP. A study from Honduras found that a high proportion of women had no evidence of CIN 2–3 at one year after thermal ablation.⁶ A more recent comparison of squamocolumnar junction ablation versus LEEP found that the ablation group had shorter procedure times, less blood loss, fewer complications, and lower cost, with similarly low rates of cytological abnormalities and lesion recurrence during follow-up.⁷ Ablation is not suitable for every patient, but when the lesion is fully visible and biopsy-confirmed, it offers a tissue-sparing option worth discussing with your clinician.

When Observation Is an Option for CIN 2

CIN 2 sits in an ambiguous zone. It falls under the HSIL umbrella, but a meaningful fraction of CIN 2 lesions clear on their own, especially in younger people. This has led many guidelines to allow active surveillance (watchful waiting with regular testing) as an alternative to immediate excision for selected patients.

How often does CIN 2 regress without treatment? The numbers vary by study. A prospective cohort study found complete regression in about 64% of surveilled CIN 2 lesions, while roughly 16% progressed to CIN 3 or worse.⁸ A ten-year retrospective analysis saw lower regression (about 17%) and persistence in the majority, with a small fraction (roughly 7%) progressing to CIN 3 or cancer.⁹ The wide range reflects differences in follow-up length, patient age, and how strictly “regression” is defined, but the general message is consistent: many CIN 2 lesions do resolve, though a minority progress, so surveillance demands reliable follow-up visits.

A Danish cohort study found similar regression rates in women younger and older than 30, suggesting that conservative management is reasonable for women of childbearing age broadly, not just teenagers.¹⁰ In the United States, updated guidelines shifted toward observation for women under 25 with CIN 2. After those guideline changes, a population-based study found that patients were more likely to receive conservative management and had higher regression rates with lower progression rates than those treated in the earlier guideline era.¹¹ CIN 3, by contrast, is almost always treated with excision because its regression rate is much lower and the risk of invasion is higher.

Reproductive Risks After Excisional Treatment

One of the biggest concerns for people treated with LEEP or CKC is the effect on future pregnancies. Removing cervical tissue can shorten or weaken the cervix, which raises questions about preterm birth and related complications. A systematic review and meta-analysis found that LEEP was associated with a preterm birth rate of about 8.8%, compared with 5.1% in untreated women, translating to roughly 1.6 times the risk.¹² However, when the comparison group was limited to women who also had a history of cervical abnormalities but were not excised, the difference in preterm birth rates shrank and lost statistical significance, suggesting that some of the risk may come from the underlying condition rather than the procedure itself.

A nationwide cohort study found that conization (either LEEP or CKC) was associated with elevated risks of cervical incompetence, preterm premature rupture of membranes, placenta previa, and intrauterine growth restriction.¹³ Another study of pregnancies after cold knife conization found higher rates of premature birth (about 14%) and premature membrane rupture (about 14%) compared with healthy controls.¹⁴ These findings reinforce why clinicians try to minimize the amount of tissue removed and why observation is favored for younger patients with CIN 2 who want to preserve fertility. If you have been treated and become pregnant, your prenatal care provider should know about your excisional history so that cervical length can be monitored.

Other Complications to Know About

Beyond reproductive effects, the most common complications of excisional procedures are bleeding and cervical stenosis (narrowing of the cervical canal). Secondary hemorrhage, meaning bleeding that starts days after the procedure rather than during it, occurs in a small percentage of LEEP patients. One comparison study reported 17 emergency admissions for secondary hemorrhage in the LEEP group, while none occurred in the CKC group.¹⁵ Cervical stenosis, which can cause painful periods or difficulty with future cervical screening, was reported in roughly 4–7% of patients in a randomized trial testing an anti-stenosis device.¹⁶ These complications are manageable, but they are worth knowing about before you consent to a procedure.

HPV Vaccination After Treatment

Perhaps the most encouraging recent development is evidence that getting an HPV vaccine after excisional treatment substantially lowers the chance of recurrence. This may seem counterintuitive if you think of vaccines as prevention-only tools, but in this case the vaccine appears to boost the immune response against HPV types that drive HSIL, reducing the risk of reinfection or reactivation of latent virus.

In a study of 286 women who underwent LEEP, those who were vaccinated afterward had a recurrence rate of about 7%, compared with roughly 17% in unvaccinated women. When the analysis looked only at recurrence of severe lesions, the protective effect was even stronger.¹⁷ A larger cohort study found that recurrence of CIN 2 or worse occurred in about 4% of vaccinated women versus roughly 12% of unvaccinated women.¹⁸ And data on timing suggest that getting vaccinated within six months after LEEP is the sweet spot for maximum benefit.² If you are being treated for HSIL and have not been vaccinated against HPV, ask your provider about this. Not every guideline has formally incorporated it yet, but the evidence is accumulating quickly.

Post-Treatment Surveillance

Treatment for HSIL is not a one-and-done event. Because recurrence happens in a meaningful minority of patients, ongoing monitoring is essential. Current protocols typically call for co-testing (a combination of HPV testing and cytology) at six-month intervals for the first two years, then annually through year five. Any abnormal result triggers a colposcopy with biopsy.¹⁹

Persistent HPV infection after LEEP is the single strongest predictor of recurrence. In one analysis, ongoing infection with the same HPV genotype carried roughly 2.5 times the risk of developing recurrent CIN 2 or worse, more than any other factor tested.¹⁹ A reassuring finding from another study is that combining HPV testing and cytology after LEEP allows women with clear results to return to routine screening intervals relatively quickly, regardless of their original margin status.²⁰ A separate study confirmed that combining HPV status with margin status at the time of conization provides the highest sensitivity for predicting recurrence within four years, allowing clinicians to tailor follow-up intensity to each patient’s risk profile.²¹

HSIL During Pregnancy

Finding HSIL during pregnancy creates a difficult balancing act. Excision during pregnancy risks bleeding and preterm labor, so the standard practice is to confirm there is no invasive cancer (through colposcopy and targeted biopsy if needed), then defer treatment until after delivery. A review of the evidence notes that more than 60% of high-grade cervical lesions regress after delivery, making conservative management during pregnancy both safe and appropriate in most cases.²² Excision is reserved for cases where biopsy suggests microinvasion or where the lesion cannot be adequately evaluated.

HSIL in People Living With HIV

HIV significantly complicates HSIL management. The weakened immune surveillance that comes with HIV means HPV infections are harder to clear, lesions recur more often, and multifocal disease (abnormalities in more than one area) is common. A study comparing recurrence after excision found that HIV-positive patients had over five times the odds of recurrence compared with HIV-negative patients. Low CD4 counts and detectable viral load further increased that risk.²³ This means that people living with HIV need closer surveillance after treatment, and keeping viral load suppressed through antiretroviral therapy is itself an important part of managing cervical disease.

HSIL Beyond the Cervix

HSIL can also develop in the anus, vulva, and vagina, and treatment strategies differ by site. Anal HSIL has become an increasing concern, particularly among men who have sex with men and people living with HIV. Treatment options include infrared coagulation, electrocautery, and topical acids like trichloroacetic acid (TCA). A systematic review found infrared coagulation to be safe and effective for destroying high-grade anal lesions, though recurrence is common and ongoing surveillance is necessary.²⁴ TCA offers a particularly low-cost option that requires no special equipment beyond what is already used during high-resolution anoscopy.²⁵

Vulvar HSIL (sometimes still called VIN, vulvar intraepithelial neoplasia) has traditionally been managed with surgical excision. But imiquimod, a cream that stimulates the local immune response, has emerged as a genuine alternative. A phase 3 randomized trial found that imiquimod produced a complete clinical and pathological response in 80% of patients, matching the 79% rate achieved by surgery, which established non-inferiority.²⁶ A smaller case series also found that 80% of vulvar HSIL patients treated with imiquimod showed at least a partial response.²⁷ For people with vulvar HSIL, the availability of a non-surgical option that avoids scarring and disfigurement is a meaningful advance.

The Emotional Side of an HSIL Diagnosis

One aspect of HSIL treatment that rarely gets enough attention is its psychological toll. An abnormal Pap smear, a colposcopy, a biopsy, waiting for results, and then being told you need a procedure to prevent cancer is a lot to process. A study measuring depression and anxiety found that the prevalence of concurrent depression and anxiety rose from about 34% before additional diagnostic workups to roughly 47% afterward, and the severity of symptoms also increased.²⁸ This is not a trivial side effect. If you are feeling anxious or overwhelmed after an HSIL diagnosis, you are far from alone, and it is worth bringing up with your provider.

See-and-Treat Versus the Traditional Three-Step Approach

In the traditional pathway for managing an abnormal Pap, you get a colposcopy, then a biopsy, wait for results, and then return for treatment if needed. This “three-step” approach is thorough but time-consuming and expensive. A “see-and-treat” alternative performs the excision at the same visit as the colposcopy, skipping the biopsy step entirely. The tradeoff is that some women end up being treated for lesions that would have turned out to be low-grade on biopsy.

A systematic review comparing the two strategies found that for patients with HSIL on cytology, the see-and-treat approach was significantly more cost-effective because it eliminated the costs of colposcopic biopsy and the associated histology, while for patients with lower-grade abnormalities, the cost-effectiveness difference between strategies was not significant.²⁹ In settings where patients face long travel distances or are at high risk of being lost to follow-up, see-and-treat can be the more practical and reliable approach, even if it means occasionally treating someone who didn’t strictly need it.